The Association Between Sarcopenia and Diabetes: From Pathophysiology Mechanism to Therapeutic Strategy
Huiling Chen,Xiaojing Huang,Meiyuan Dong,Song Wen,Ligang Zhou,Xinlu Yuan
DOI: https://doi.org/10.2147/DMSO.S410834
2023-05-30
Abstract:Huiling Chen, 1, 2 Xiaojing Huang, 2 Meiyuan Dong, 2 Song Wen, 2 Ligang Zhou, 2 Xinlu Yuan 2 1 Graduate School of Fudan University, Shanghai, People's Republic of China; 2 Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, People's Republic of China Correspondence: Xinlu Yuan, Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, People's Republic of China, Tel +8613370211617, Email Diabetes and sarcopenia are emerging as serious public health issues. Sarcopenia, an age-related disorder characterized by loss of skeletal muscle mass and function, is recognized as a new complication in elderly patients with type 2 diabetes mellitus (T2DM). Type 2 diabetes is characterized by insulin resistance, chronic inflammation, accumulation of advanced glycation products and increased oxidative stress, which can negatively affect skeletal muscle mass, strength and function leading to sarcopenia. There is a mutual interrelationship between T2DM and sarcopenia in light of pathophysiology mechanism and long-term outcome. T2DM will accelerate the decline of muscle mass and function, which will in turn lead to glucose metabolism disorders, reduced physical activity and the risk of diabetes. However, the specific mechanism involved has not been thoroughly studied. Therefore, this review aims to explore the pathophysiology and therapeutic strategy related to sarcopenia and diabetes and provide insight for future investigations, which is of great significance for improving the quality of life in the elderly with diabetes and concurrently reducing the incidence of related complications. Keywords: type 2 diabetes mellitus, sarcopenia, insulin resistance, inflammation, gut microbiota, therapeutic strategy Type 2 Diabetes mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia due to insulin secretion and (or) utilization disorders. Epidemiological evidence shows that about 387 million adults are suffering from DM worldwide, 1 and it is estimated that it will increase to 693 million by 2045, 2 which has greatly burdened patients and society. Studies have found that both men and women with diabetes have lower bone mass index values 3 and the risk of sarcopenia in patients with T2DM is 1.5–2 times higher than that of non-diabetic people. 4 Currently, sarcopenia has been regarded as a new complication of T2DM, 5 which not only leads to poor quality of life but also increases the risk of physical disability and even death. 6–8 The Asian Working Group for Sarcopenia (AWGS) 2014 consensus defined sarcopenia as "age-related decline of skeletal muscle plus low muscle strength and/or physical performance", 9 which refers to age-related syndrome of progressive skeletal muscle loss with decrease in muscle strength and/or muscle function. It is a progressive and systemic skeletal muscle disorder that usually occurs as an age-related process in older adults 10 and is associated with serious consequences in the elderly such as frailty, falls, fractures, physical disability and death. 11,12 According to the latest diagnostic criteria of the Asian Working Group on Sarcopenia (AWGS) in 2019, the prevalence rates of suspected sarcopenia, sarcopenia, and severe sarcopenia in China are 38.5%, 18.6%, and 8.0%, respectively. 13 It is estimated that the prevalence of sarcopenia will increase significantly within the next 30 years, 14 becoming a major public issue. Sarcopenia and T2DM have a bidirectional relationship, 15 increase the risk of each other 16 and lead to functional decline and disability. 17 Recent studies have shown that patients with T2DM and sarcopenia have a higher mortality rate than those without sarcopenia. 18 However, little attention has been paid to elderly T2DM patients with sarcopenia. Hence, it is important to study the pathogenesis of both for a proper management of this clinical complexity. Aging is one of the most important risks of diabetes and sarcopenia. 19 One remarkable physiological sign of the aging process is the gradual loss of skeletal muscle mass and function, 20 which latently onset around the age of 30, 21 and will accumulate to 30–50% extremely loss in 80 years old. 22 The partial mechanism for this phenomenon may lie in the skeletal muscle, the major organ that possesses glucose transporter 4 (GLUT4) responsible for uptake of glucose, accounting for approximately 80% of glucose clearance, 23,24 and the utility of glucose also latently declines, increasing susceptibility to T2D. 25 Unlike muscle tissue, the transformatio -Abstract Truncated-
endocrinology & metabolism